Sonoma Biotherapeutics
Latest round
- Series B
Last raised
- Jul 2021
Total raised
- $335M
Investors
- 24
About Sonoma Biotherapeutics
Based in California, US, and founded in 2020, Sonoma Biotherapeutics, Inc. develops adoptive Treg therapies cell for autoimmune and inflammatory diseases. The company was co-founded by Alexander Rudensky, Fred Ramsdell, Jeffrey Bluestone (CEO), and Qizhi Tang. The company's programs include SBT-77-7101, a novel CAR-based Treg cell therapy for patients with refractory rheumatoid arthritis, SBT-11-5301, a Teff conditioning biologic designed to help clear the inflammatory environment and make Treg cell therapies effective, and SBT-77-7200 Series for other autoimmune and inflammatory diseases. The company plans to advance its Bio’s Treg cell therapy platform and a novel Teff conditioning biologic into the clinic to treat multiple, severe autoimmune, and inflammatory diseases, and to further invest in and further enhance its manufacturing operations in order to support supply for initial clinical studies.
Who invested in Sonoma Biotherapeutics
24 investors across 3 rounds
See all investors in Sonoma Biotherapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Sonoma Biotherapeutics
Who invested in Sonoma Biotherapeutics?
Sonoma Biotherapeutics has 24 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Sonoma Biotherapeutics raised?
Sonoma Biotherapeutics has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Sonoma Biotherapeutics last raise money?
Sonoma Biotherapeutics's most recent round on record is a Series B, in Jul 2021.
What does Sonoma Biotherapeutics do?
Based in California, US, and founded in 2020, Sonoma Biotherapeutics, Inc.
Where is Sonoma Biotherapeutics headquartered?
Sonoma Biotherapeutics is headquartered in South San Francisco, US.
Which VCs invest in companies like Sonoma Biotherapeutics?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Sonoma Biotherapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Sonoma Biotherapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.